Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL958781 | 1.00 | CA1 (0.31) | CA1CA2CA4EPHX1TRPA1 | |
| SCHEMBL4608681 | 1.00 | CA1 (0.31) | CA1CA2CA4EPHX1TRPA1 | |
| SCHEMBL20930020 | 1.00 | CA1 (0.31) | CA1CA2CA4EPHX1TRPA1 | |
| SCHEMBL8204015 | 1.00 | CA1 (0.31) | CA1CA2CA4EPHX1TRPA1 | |
| SCHEMBL1276250 | 1.00 | CA1 (0.31) | CA1CA2CA4EPHX1TRPA1 | |
| SCHEMBL20930152 | 1.00 | CA1 (0.31) | CA1CA2CA4EPHX1TRPA1 | |
| SCHEMBL696325 | 0.86 | CYP1A2 (0.33) | — | |
| SCHEMBL9240986 | 0.82 | — | — | |
| SCHEMBL7941765 | 0.82 | — | — | |
| SCHEMBL9240998 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3100723-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | BIKAM PHARMACEUTICALS INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-9562022-B2 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| EP-3100723-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2442644-B1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS INC (US) | 2016-08-10 | — | — | EP | disclosed |
| EP-2442644-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. | 2011-01-06 | — | — | US | disclosed |
| WO-2010147653-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| EP-1347035-B1 | Isomer composition containing optically active ethyl trans-2,2,6-trimethylcyclohexylcarboxylate and fragrance composition containing the isomer composition | TAKASAGO PERFUMERY CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| EP-1347036-B1 | Isomer composition excellent in chemical resistance containing optically active trans-1(2,2,6-trimethylcyclohexyl)-2-buten-1-one and fragrance composition containing the isomer composition | TAKASAGO PERFUMERY CO LTD (JP) | 2008-06-25 | — | — | EP | disclosed |
| EP-0449034-B1 | Cyclic ketones, method for their preparation and their application in perfumery | FIRMENICH & CIE (CH) | 1994-12-28 | — | — | EP | disclosed |
| US-5118865-A | CYCLIC KETONES AND THEIR USE AS PERFUMING INGREDIENTS | FIRMENICH SA (CH) | 1992-06-02 | — | — | US | disclosed |
| EP-0449034-A1 | Cyclic ketones, method for their preparation and their application in perfumery | FIRMENICH SA (CH) | 1991-10-02 | — | — | EP | disclosed |
| EP-0118809-B1 | COMPOSITION ESSENTIALLY CONSISTING OF TRANS-1-(2,6,6-TRIMETHYLCYCLOHEXYL)-HEXAN-3-OL, UTILIZATION OF SAME AND PROCESS FOR ITS PREPARATION; CYCLOALIPHATIC KETONE AND ALCOHOL INTERMEDIATES | FIRMENICH SA (CH) | 1988-05-11 | — | — | EP | disclosed |
| US-4711875-A | PERFUMES | FIRMENICH SA (CH) | 1987-12-08 | — | — | US | disclosed |
| US-4623750-A | PERFUMES | FIRMENICH SA (CH) | 1986-11-18 | — | — | US | disclosed |
| EP-0118809-A2 | Composition essentially consisting of trans-1-(2,6,6-trimethylcyclohexyl)-hexan-3-ol, utilization of same and process for its preparation; cycloaliphatic ketone and alcohol intermediates | FIRMENICH SA (CH) | 1984-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037018-A1 | Opsin-Binding Ligands, Compositions and Methods of Use | CRYAB, CRYAA, UACA | CA1 4482/4885CA2 2704/4885CA4 4181/4885 |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | CRYAB, CRYAA, UACA | CA1 4482/4885CA2 2704/4885CA4 4181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.